Article info

Download PDFPDF

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

Authors

  1. Correspondence to Dr Bradley J Monk, Arizona Oncology (US Oncology Network), 2222 E Highland Avenue, Suite 400, Phoenix, AZ 85016, USA; bradley.monk{at}usoncology.com
View Full Text

Citation

Monk BJ, Coleman RL, Fujiwara K, et al
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

Publication history

  • Accepted August 11, 2021
  • First published September 30, 2021.
Online issue publication 
December 06, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.